CORE--CLINICAL

核心--临床

• 批准号: 6102375
• 负责人: BRITT-MARIE E. LJUNG
• 金额: $ 23.3万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2001-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6102375
• 关键词: biomedical facility; breast neoplasm /cancer diagnosis; breast surgery; cancer information system; cytogenetics; histopathology; human subject; metastasis; neoplasm /cancer genetics; tissue resource /registry

The Clinical Program Core will provide tissue material from surgically excised specimens from women with primary breast cancer. The tissue will include a portion of the tumor, benign appearing breast tissue, skin and, when available, metastatic disease in lymph nodes. Special care will be taken to utilize tissue in an optimal way so that small tumors (~1 cm in diameter) can be included in the study without jeopardizing morphologic diagnosis. This will be achieved by using optimal dissection techniques and continuous updating of the tissue needs of the various research projects. The core will do the initial processing, including in vitro BrdUrd incorporation for study of proliferation and distribution of tissue to the projects. Patients suitable for the in vivo BrdUrd protocol will be identified, prepared, and administered the drug. Blood from patients with breast cancer, and from their parents, when feasible and possible, will be taken for cytogenetic studies. The clinical core will also conduct detailed histologic analyses of all cases and enter the resulting data into the database.

临床程序核心将通过手术提供组织材料 从原发性乳腺癌女性中切除标本。 组织会 包括一部分肿瘤，良性出现乳房组织，皮肤和， 如果有的话，淋巴结中的转移性疾病。 特殊护理将是 以最佳方式利用组织，以使小肿瘤（约1厘米处 直径）可以包括在研究中，而不会危及形态学 诊断。 这将通过使用最佳解剖技术来实现 并不断更新各种研究的组织需求 项目。 核心将进行初始处理，包括体外Brdurd 纳入组织的增殖和分布到 项目。 适合体内BRDURD方案的患者将是 鉴定，准备和服用该药物。 患者的血液 乳腺癌以及父母的可行和可能的可能是 进行细胞遗传学研究。 临床核心也将进行 所有情况的详细组织学分析，并将结果数据输入到 数据库。